Iradimed (46K) Stock Statistics & Valuation Metrics
Total Valuation
Iradimed has a market cap or net worth of EUR 877.94M. The enterprise value is EUR 1.05B.
- Market Cap
- EUR 877.94M
- Enterprise Value
- EUR 1.05B
Share Statistics
Iradimed has 12,786,991 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,786,991
- Owned by Insiders
- 34.85%
- Owned by Institutions
- 28.16%
Financial Efficiency
Iradimed’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 21.02%.
- Return on Equity (ROE)
- 0.24
- Return on Assets (ROA)
- 0.21
- Return on Invested Capital (ROIC)
- 21.02%
- Return on Capital Employed (ROCE)
- 0.27
- Revenue Per Employee
- 504.90K
- Profits Per Employee
- 135.42K
- Employee Count
- 166
- Asset Turnover
- 0.77
- Inventory Turnover
- 1.68
Valuation Ratios
The current PE Ratio of Iradimed is 40.57. Iradimed’s PEG ratio is 3.08.
- PE Ratio
- 40.57
- PS Ratio
- 10.97
- PB Ratio
- 9.21
- Price to FCF
- 37.79
- Price to Operating Cash Flow
- 36.12
- PEG Ratio
- 3.08
Income Statement
In the last 12 months, Iradimed had revenue of 83.81M and earned 22.48M in profits. Earnings per share was 1.77.
- Revenue
- 83.81M
- Gross Profit
- 64.32M
- Operating Income
- 26.15M
- Pretax Income
- 28.36M
- Net Income
- 22.48M
- EBITDA
- 29.53M
- Earnings Per Share (EPS)
- 1.77
Cash Flow
In the last 12 months, operating cash flow was 27.15M and capital expenditures -1.20M, giving a free cash flow of 25.95M billion.
- Operating Cash Flow
- 27.15M
- Free Cash Flow
- 25.95M
- Free Cash Flow per Share
- 2.03
Dividends & Yields
Iradimed pays an annual dividend of ―, resulting in a dividend yield of 1.42%
- Dividend Per Share
- ―
- Dividend Yield
- 1.42%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.55%
- Earnings Yield
- 2.36%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- 13.43%
- 50-Day Moving Average
- 74.54
- 200-Day Moving Average
- 78.84
- Relative Strength Index (RSI)
- 49.55
- Average Volume (3m)
- 3
Important Dates
Iradimed upcoming earnings date is Feb 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Iradimed as a current ratio of 7.98, with Debt / Equity ratio of 0.00%
- Current Ratio
- 7.98
- Quick Ratio
- 6.84
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.73
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Iradimed has paid 5.88M in taxes.
- Income Tax
- 5.88M
- Effective Tax Rate
- 0.21
Enterprise Valuation
Iradimed EV to EBITDA ratio is 29.92, with an EV/FCF ratio of 36.74.
- EV to Sales
- 10.67
- EV to EBITDA
- 29.92
- EV to Free Cash Flow
- 36.74
- EV to Operating Cash Flow
- 35.12
Balance Sheet
Iradimed has EUR 63.29M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 63.29M billion.
- Cash & Marketable Securities
- EUR 63.29M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 63.29M
- Net Cash Per Share
- EUR 4.95
- Tangible Book Value Per Share
- EUR 8.06
Margins
Gross margin is 75.51%, with operating margin of 32.30%, and net profit margin of 26.85%.
- Gross Margin
- 75.51%
- Operating Margin
- 32.30%
- Pretax Margin
- 34.83%
- Net Profit Margin
- 26.85%
- EBITDA Margin
- 35.67%
- EBIT Margin
- 34.27%
Analyst Forecast
The average price target for Iradimed is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- 5.57%
- EPS Growth Forecast
- 7.32%
Scores
- Smart Score
- 5
- AI Score
- ―
